A significant proportion of patients with rheumatic diseases are women of childbearing age, and the impact of rheumatic diseases on fertility is an important issue in their lives. Previous studies have shown that systemic lupus erythematosus (SLE) has a negative impact on fertility, and more recent studies suggest that other rheumatic diseases also have a negative impact on fertility. A 2015 article published in Reumatology reported that rheumatoid arthritis (RA), leukoarthritis (BD), and spondyloarthropathy (SpA) have a negative impact on ovarian reserve function in premenopausal women. In this article, anti-Mullerian’s hormone (AMH) was used as an index to evaluate ovarian reserve function, and AMH < 1.0 ng/ml suggested a decrease in ovarian reserve function. Anti-Mullerian hormone (AMH) is currently the most reliable indicator of ovarian reserve function, which is an indicator of how many primordial follicles are left to produce eggs, and the number of primordial follicles ceases to increase after birth, and women enter menopause when they are depleted. The results of the article found that AMH levels were significantly lower in patients with rheumatoid arthritis, leukoarthritis, and SpA compared to healthy individuals, with 50% of patients with leukoarthritis, 30% of patients with rheumatoid arthritis, and 37.5% of patients with spondyloarthropathy having AMH < 1.0 ng/ml, which means that ovarian reserve function is reduced. And AMH levels were significantly lower in HLA-B27SpA-positive patients than in B27-negative spondyloarthropathies. However, the duration of disease in all three diseases had no effect on AMH levels. This suggests that patients with rheumatoid arthritis (RA), leukoarthrosis (BD), and spondyloarthropathies (SpA) have fewer years of childbearing and may enter menopause earlier. Previous studies have reported a significant negative effect of SLE on ovarian reserve function in premenopausal women, and even SLE patients with mild disease activity had a significant decrease in ovarian reserve function compared to healthy individuals of the same age; the decrease in ovarian reserve function was even more pronounced in SLE patients treated with cyclophosphamide (CTX), and the level of decrease in AMH was proportional to the CTX The cumulative dose of methotrexate (MTX) was also associated with a decrease in ovarian reserve in patients with SLE with childhood onset. A decrease in AMH levels and impaired ovarian reserve function has been reported in patients with aortitis compared to healthy subjects; AMH levels were not associated with disease activity or methotrexate treatment in patients with aortitis. One study reported a decrease in AMH levels and impaired ovarian reserve function in patients with necrotizing granulomatous vasculitis (also known as Wegener's granulomatosis) treated with cyclophosphamide, but not in patients receiving methotrexate. One study found that 50% of patients with leukoaraiosis had AMH <1.0 ng/ml compared to 19% of the healthy control population, suggesting that leukoaraiosis also causes a decrease in ovarian reserve function. In conclusion, in addition to SLE, other common rheumatic diseases such as rheumatoid arthritis, leukoarthritis, vasculitis, and spondyloarthropathies also have a negative impact on ovarian reserve function in women, making these women face a reduced number of years of childbearing and an increased risk of infertility. The rheumatology drugs may worsen this situation and require the attention of patients and rheumatologists.